Form 8-K - Current report:
SEC Accession No. 0001213900-24-102903
Filing Date
2024-11-26
Accepted
2024-11-26 17:00:55
Documents
18
Period of Report
2024-11-26
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0222547-8k_pasithea.htm   iXBRL 8-K 37233
2 ATM AGREEMENT, DATED NOVEMBER 26, 2024, BY AND BETWEEN PASITHEA THERAPEUTICS COR ea022254701ex1-1_pasithea.htm EX-1.1 222898
3 OPINION OF LOWENSTEIN SANDLER LLP ea022254701ex5-1_pasithea.htm EX-5.1 9642
4 GRAPHIC ex5-1_001.jpg GRAPHIC 12233
5 GRAPHIC ex5-1_002.jpg GRAPHIC 15032
  Complete submission text file 0001213900-24-102903.txt   589214

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE ktta-20241126.xsd EX-101.SCH 3810
7 XBRL DEFINITION FILE ktta-20241126_def.xml EX-101.DEF 26681
8 XBRL LABEL FILE ktta-20241126_lab.xml EX-101.LAB 36819
9 XBRL PRESENTATION FILE ktta-20241126_pre.xml EX-101.PRE 25305
20 EXTRACTED XBRL INSTANCE DOCUMENT ea0222547-8k_pasithea_htm.xml XML 5941
Mailing Address 2110 NARCISSUS CT VENICE CA 90291
Business Address 2110 NARCISSUS CT VENICE CA 90291 8184226172
Pasithea Therapeutics Corp. (Filer) CIK: 0001841330 (see all company filings)

EIN.: 851591963 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40804 | Film No.: 241505114
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)